Continuous monitoring of jugular bulb oxygen saturation as a measure of the shunt flow of cerebral arteriovenous malformations.

Jugular bulb oxygen saturation (SjO2) was monitored during preoperative embolization procedures in a consecutive series of 15 patients with large supratentorial arteriovenous malformations (AVM's) in order to test the hypothesis that changes in the shunt flow ratio can be continuously evaluated from the SjO2. A fiberoptic catheter was placed at the dominant jugular bulb. The SjO2 measured using jugular blood withdrawn before embolization was significantly higher than the SjO2 measured at the end of the final embolization procedure (mean +/- standard deviation 84.1% +/- 12.7% vs. 74.2% +/- 10.9%, p < 0.0001), showing a positive correlation with the AVM volume (r = 0.66, p < 0.001). Continuous monitoring of SjO2 via the fiberoptic catheter revealed a progressive decrease in association with the embolization procedures. Microsurgical resection of the AVM was performed at 1 to 2 weeks after the final embolization. Cases in which postoperative hemispheric deformation was revealed on computerized tomography demonstrated a higher SjO2 at the end of embolization compared to that in the remaining cases (81.6% +/- 8.6% vs. 67.8% +/- 8.4%, p < 0.008). Hemispheric deformation was observed in all cases in which the SjO2 did not decline to a level below 90% following embolization. The risk of severe hyperemic complications appeared to be greatly diminished when the SjO2 fell to below 80%. Assuming that the oxygen saturation of the perfusion flow (SjpO2) ranges from 50% to 75%, the ratio of the shunt flow to total flow at an SjO2 of 90% was estimated to be 0.6 to 0.8 based on the following equation: shunt flow/(perfusion flow + shunt flow) = (SjO2 - SjpO2)/(arterial oxygen saturation - SjpO2). These results suggest that monitoring the SjO2 provides real-time information concerning the progress of embolization and helps to determine whether the embolization has progressed sufficiently to avoid postoperative hyperemic complications.